A Brief Description of Pharmacoeconomics.pdf

As a consequence of limited financial resources, health economics, and particularly pharmacoeconomic analyses, are becoming a frequently used criterion for decision making in modern health care policy. The pharmacoeconomic studies cannot be universal and their results are impossible to be directly transferred beyond the study setting. This article draws the readers' attention to the main components of pharmacoeconomic studies, which have an influence on the generalisability of the results. The aim is for the readers to get an idea as to what extent pharmacoeconomic results are correct and how these correspond to their own setting.

2015

The rising cost of healthcare delivery systems is a major concern to all patients, healthcare professionals, and the government. The demand for and the cost of health care are increasing in all countries as the improvement in and sophistication of health technologies. The increase in health care spending is mainly because of increased life expectance, increased technology, increased standard of living and increased demand in health care quality and services. Medicines form a small but significant proportion of total health care cost. As the affordability of new medical technologies continues to be the subject of heated debate, attention is also increasingly focused on providing quality and cost-effective healthcare. Economic evaluation of pharmaceutical products, or pharmacoeconomics, is a rapidly growing area of research. Pharmacoeconomic evaluation is important in helping clinicians and decision makers to make choices about new pharmaceutical products and in helping patients obtai...

British Journal of Clinical Pharmacology, 1997

2013

CITATIONS 0 READS 102 6 authors, including:

Pharmacoeconomics has been defined as the description and analysis of the cost of drug therapy to healthcare systems and society. More specifically, pharmacoeconomic research is the process of identifying, measuring, and comparing the costs, risks, and benefits of programs, services, or therapies and determining which alternative produces the best health outcome for the resource invested. For most practitioners, this translates into weighing the cost of providing a pharmacy product or service against the consequences (outcomes) realized by using the product or service to determine which alternative yields the optimal outcome per dollar spent. This information can assist clinical decision makers in choosing the most cost-effective treatment options.

PharmacoEconomics, 1998

The need to demonstrate the cost effectiveness of healthcare interventions has led to a rapid increase in the use of economic tools within pharmaceutical evaluations. Pharmacoeconomics is employed at many stages of the evaluation process, helping to predict which products are likely to be economically viable at an early stage, and providing information to aid price and reimbursement negotiations as well as formulary and purchasing decisions in conjunction with phase III and IV clinical trials.

PHARMACOECONOMICS: theory and practice, 2016

The increase of practical application of pharmacoeconomics in the organiza- tion of medicinal provision the Russian Federation requires clarification of the definition of the concepts of pharmacoeconomics. Thus, in the context of the academic approach the term «pharmacoeconomics» can be defined as an in- dependent science that studies in comparative terms the ratio between cost and effectiveness, safety and quality of life of patients with different treatment regimens or disease prevention. However, from the perspective of practical ap- plication it will be more accurate to consider pharmacoeconomics as a tool for decision support, providing decision-makers, relevant and reliable information in order to create from them a clear understanding of the situation and the pos- sibility of taking appropriate optimal solutions. Herewith, wide opportunities of pharmacoeconomics are based on the application of pharmacoeconomic mod- eling. In this connection, the authors, based on their own pr...

Procedia Economics and Finance, 2015

By today, in our business environment, mostly based on innovation, the potential opportunities in the pharmaceutical sector and impact of these to the national economic trends has a determining significance. National and international importance of the pharmaceutical industry defined by not only the prominent role of application of the biochemical academic research, but also the humanitarian concerns which increasingly appreciating in the global context. These facts-in view of growing efficient immune substances developing procedures-are stronger pressure on the industrial actors, with this affecting the profitability of future operations. Broader sense pharmacoeconomics includes the examination of the main factors which influence the change of expenditures produced in the health system, furthermore compares the value of different pharmaceutical drugs or drug therapies by using many analytical methods such as cost minimalization analysis, cost benefit analysis, cost effectiveness analysis and the cost utility analysis. Our analysis is mostly theoretical.

Health Economics, 1999

Disease Management and Health Outcomes, 2002

Increased worldwide cost consciousness with regard to healthcare spending has resulted in a greater reliance of health systems on pharmacoeconomics as a tool for obtaining optimal value, attaining better outcomes, and controlling spending. In such capacities, pharmacoeconomics is often used as a basis for pricing, purchasing, and reimbursement decisions. Current barriers to the use of pharmacoeconomic data are related to the international coexistence of various evolutionary states of the theory and implementation of pharmacoeconomics, the fragmentation of healthcare budgets, and the diversity of healthcare systems and clinical settings. One result of these barriers is the decision makers' need for more rigorous, more directly relevant pharmacoeconomic data that are presented in an interactive, customizable manner. Other stakeholders in the healthcare market have been noticeably affected by decision makers' use of pharmacoeconomics and the more stringent data demands. Physicians have experienced decreased autonomy, patients have experienced delayed drug access and possibly compromised care, and manufacturers have endured greater financial burden and risk. This paper identifies ways in which manufacturers can maximize the effectiveness of their pharmacoeconomic activities to efficiently meet decision-maker needs, overcome some of the current barriers to the use of pharmacoeconomics, and minimize deleterious effects on major healthcare stakeholders.